2021 Egypt Tumor Marker Market Assessment--Oncogenes, Bio Markers, GFs, CSFs, Hormones, Stains, Lymphokines--Competitive Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

The report is available by section, and can be customized to specific information needs and budget.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

- Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

- Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

- Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contains 535 pages and 70 tables

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

I. Inroducion
II. Marke Overview
III. Major Produc Developmen Opporuniies
IV. Design Crieria for Decenralized esing Producs
V. Alernaive Marke Peneraion Sraegies
VI. Poenial Marke Enry Barriers and Risks
VII. Major Curren and Emerging Cancer Diagnosic ess
1. Inroducion
2. Cancer Diagnosic Classificaion
3. ACH
4. Alpha-Feoproein (AFP)
5. Bea-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcionin
10. Carcinoembrionic Anigen (CEA)
11. Esrogen and Progeserone Recepors
12. Ferriin
13. Gasrin
14. Human Chorionic Gonadoropin (HCG)
15. Insulin
16. NSE
17. Occul Blood
18. PAP Smear/HPV
19. Prosaic Acid Phosphaase (PAP)
20. Prosae-Specific Anigen (PSA)
21. Squamous Cell Carcinoma Anigen (SCC)
22.  and B Lymphocyes
23. d
24. hyroglobulin
25. issue Polypepide Anigen (PA)
26. Biochemical Cancer Diagnosics
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PI-1
- Ras
- Reg
- Sis
- Src and ohers
28. Polypepide Growh Facors
- Basic Fibroblas Growh Facor
- Bea-GF
- Cachecin (N)
- Calmodulin
- ECFR
- Nerve Growh Facor (NGF)
- Epidermal Growh Facor (EGF)
- Ornihine Decarboxylase
- ransferrin
- ransforming Growh Facor-Alpha
29. Ecopic Hormones
30. Colony Simulaing Facors
31. Lymphokines
- Alpha-Inerferon
- B Cell Growh Facors
- B Cell Growh Facor (BCGF)
- Gamma-Inerferon
- Inerleukin-1 (IL-1)
- Macrophage Acivaing Facor
32. Immunohisochemical Sains
33. Emerging Cancer Diagnosics
- N-Aceylglucosamine
- Acin
- Alpha-Acin
- Anineuronal Anibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Anigens A,B,H
- CA 50
- CA 72-4/AG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cahepsin-D
- Chromogranin A and B
- Cluser 1 Anigen
- Cluser-5/5A Anigen
- CA
- CU18
- DR-70
- DU-PAN-2
- Endomerial Bleeding Associaed Facor
- Endosain
- Epihelial Membrane Anigen
- Feulgen Hydrolysis
- Fibronecin
- FSH
- (1->3)-L-fucosylransferase
- Gasrin-Releasing Pepide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Anigen
- HPA
- HSP27
- Inermediae Filamens
- Cyokerains/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Proein
- Neurofilamens
- Vimenin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocye Common Anigen
- Lewis Anigens
- Lysophosphaidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minacivin
- MN/CA9
- MSA
- Mucin Cancer Anigen (MCA)
- Muliple umor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Pepides
- P-glycoproein
- Pancreaic Oncofeal Anigen (POA)
- Placenal Lacogen
- PR92
- Proliferaive Index, Ki-67
- Px
- RB Inacivaion/Deleion
- Re
- SCCL 175
- Selecin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somaosain
- A-90
- ABA
- achykinin
- AG 12
- PS
- roponin
- ubulin
- VCAM
- VEGF
- Villen and ohers
VIII. Insrumenaion Review and Marke Needs
IX. Curren and Emerging echnologies
1. Monoclonal and Polyclonal Anibodies
2. Immunoassays
3. Molecular Diagnosics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acue Myeloid Leukemia (AML)
c. Acue Lymphoblasic Leukemia (ALL)
d. Malignan Lymphomas Lymphoid Malignancies
e. Chronic Lymphocyic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal ranslocaion and Oncogenes
5. Arificial Inelligence
6. Flow Cyomery
7. wo Dimensional Gel Elecrophoresis (2-DGE)
8. Biosensors
9. Compeing/Complemening echnologies
X. Marke Size, es Volume and Sales Forecass
XI. Compeiive Profiles
he repor provides sraegic assessmens of over 30 leading cancer diagnosics marke players and
sar-up companies wih innovaive echnologies and producs, including:
- Abbo
- Affymerix
- Beckman Couler/Danaher
- Becon Dickinson
- bioMerieux
- Bio-Rad
- Cepheid
- DiaSorin
- Eiken Chemical
- Eliech Group
- Enzo Biochem
- Fujirebio
- Grifols
- Hologic
- Leica Biosysems
- Orho-Clinical Diagnosics
- PerkinElmer
- Qiagen
- Roche
- Siemens Healhineers
- akara Bio
- hermo Fisher
- Wako and ohers.

List Of Tables

Cancer Diagnostic Test Volume and Sales Forecasts
Cancer Diagnostic Volume Forecast by Test
Cancer Diagnostics Sales Forecast by Test
Cancer Diagnostic Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Sub-classification Tests
Biochemical Markers Potential Applications in Cancer Diagnosis
Oncogenes Potential Applications in Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications in Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications in Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Fill The Form For Sample Request

There is no Reviews available